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Objectives The aim of this study was to address the knowledge gap using the APEX-AMI (Assess-
ment of Pexelizumab in Acute Myocardial Infarction) trial database. We also assessed the association
between serious infections and 90-day death or death/myocardial infarction (MI).
Background Little is known about the incidence, location, etiological organisms, and outcomes of
infection in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary
percutaneous coronary intervention.
Methods We analyzed data from 5,745 STEMI patients enrolled in the APEX-AMI trial. Detailed infor-
mation on infection was collected for all patients. We described characteristics of patients according
to infection and details of infection. Cox proportional hazards models were used to assess 90-day
outcomes among patients with and without infections after adjusting for associated clinical variables
and with infection as a time-dependent covariate.
Results Overall, 138 patients developed a serious infection (2.4%), most of whom presented with a
single-site infection. The median (25th, 75th percentile) time until diagnosis of infection was 3 (1, 6)
days. The most commonly identiﬁed organism was Staphylococcus aureus, and the main location of
infection was the bloodstream. These patients had more comorbidities and lower procedural success
at index percutaneous coronary intervention than those without infections. Serious infection was
associated with signiﬁcantly higher rates of 90-day death (adjusted hazard ratio: 5.6; 95% conﬁdence
interval: 3.8 to 8.4) and death or MI (adjusted hazard ratio: 4.9; 95% conﬁdence interval: 3.4 to 7.1).
Conclusions Infections complicating the course of patients with STEMI were uncommon but associated with
markedly worse 90-day clinical outcomes. Mechanisms for early identiﬁcation of these high-risk patients as
well as design of strategies to reduce their risk of infection are warranted. (Pexelizumab in Conjunction
With Angioplasty in Acute Myocardial Infarction [APEX-AMI]; NCT00091637) (J Am Coll Cardiol Intv
012;5:769–76) © 2012 by the American College of Cardiology Foundation
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770Rates of infection complicating percutaneous coronary in-
tervention (PCI) are very low (1–9), and reported rates of
infection in patients undergoing cardiac catheterization are
1% (10–12). Cardiogenic shock complicating acute myo-
cardial infarction (MI) is often accompanied by a systemic
inflammatory response, manifested by high levels of
interleukin-6 and associated with multi organ failure and
high mortality rates (13–15). The extent of overlap between
cardiogenic shock and other conditions leading to a systemic
inflammatory state, including serious infection, is unclear.
In 1 report, among patients with cardiogenic shock com-
plicating ST-segment elevation myocardial infarction
(STEMI), 21% died of noncar-
diac causes, and the cause of
death was sepsis in 29% (13).
Little is known about the in-
cidence, location, demographic
data, and etiological organisms
of serious infection in patients
with acute MI, particularly
STEMI, who are treated with
primary PCI in the contempo-
rary era. Thus, the primary ob-
jective of our study was to ad-
dress this knowledge gap with
the database of the APEX-AMI
(Assessment of Pexelizumab in
Acute Myocardial Infarction)
trial. We also assessed the asso-
ciation between serious infection
and 90-day death or death/MI.
Methods
We analyzed data from the
APEX-AMI trial, a randomized
clinical trial of 5,745 STEMI
patients treated with primary
PCI. Briefly, the APEX-AMI
trial was a multicenter (17 coun-
tries and 296 hospitals), ran-
domized, double-blind trial of
pexelizumab versus placebo in conjunction with primary
PCI in STEMI. The trial was approved by the institutional
ethics committee or institutional review board of each
participating site, and all enrolled patients provided written
informed consent. The present analyses were approved by
the institutional review board of Duke University Medical
Center. The primary outcome of the APEX-AMI trial was
30-day mortality. Secondary outcomes were 90-day mortal-
ity and the composite of death, cardiogenic shock, and
congestive heart failure at 30 days. Additional outcomes
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BP  blood pressure
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CHF  congestive heart
failure
CI  confidence interval
COPD  chronic obstructive
pulmonary disease
ECG  electrocardiograph
HR  hazard ratio
ICH  intracerebral
hemorrhage
MI  myocardial infarction
MRI  magnetic resonance
imaging
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionincluded stroke, recurrent MI, and sepsis. In this largeclinical trial, no difference in 30-day mortality was observed
between the 2 randomized treatment groups (16).
Because pexelizumab is an inhibitor of C5 complement
activation, resulting in formation of C5a (anaphylatoxin and
proinflammatory substance) and C5b-9 or the membrane
attack complex, patients with known or suspected active
serious infection were excluded from the trial before ran-
domization, and detailed information about the occurrence
of infection during and after treatment was collected (16).
Data on serious infections were categorized in the case
report form as follows: sepsis with and without shock,
pneumonia, cellulitis, sternal wound, puncture site, and
other. If a culture was obtained, the site of the culture
(blood, urine, sputum, or wound), type of organism detected
by the culture, date of infection, whether the investigator
determined the infection was related to the study drug, and
outcome were recorded. Infections were also collected as
adverse events (serious or non serious). These were catego-
rized by the Medical Dictionary for Regulatory Activities
system organ class, high-level, and preferred term. Both
sources of infection diagnosis were used for our analysis.
“Serious infection” was determined by the investigator
and was not centrally adjudicated. However, all in-hospital
data from the case report forms were source data verified.
Discrepant data with regard to infection were reconciled,
and extensive data queries were performed to verify the data.
Although analysis of infection was not part of the formal
statistical plan, we did plan to investigate events, such as
serious infections that were prospectively collected as “yes”
or “no” variables on the case report form.
Statistical analysis. Continuous variables were presented as
median (25th, 75th percentile). Nonparametric p values
were given for comparing continuous variables. Categorical
variables were presented as percentages and were compared
using chi-square or exact p values. A frequency table was
provided for number of infections, time from randomization
to infection (in days), infection site (e.g., urine, blood-
stream, and others), and infectious organism.
Tables of outcomes and concomitant medications were
also provided. The p values were omitted from these tables
because they included time-dependent covariates with un-
recorded times, and it was unclear whether infection strictly
preceded the outcome/medication dosing. A Cox propor-
tional hazards model was fit for 90-day death and 90-day
death or MI with infection as a time-dependent covariate.
The model was adjusted for “sheath time” (the time a
patient was undergoing catheterization/PCI and had an
in-dwelling catheter) and other variables previously deter-
mined to be significant predictors of death in the APEX-
AMI trial: age, baseline Killip class III or IV, baseline
systolic blood pressure, baseline heart rate, and baseline
creatinine level (17). Hazard ratios (HRs) and correspond-
ing 95% confidence intervals (CIs) were reported. The
model was fit both including and excluding early deaths
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771(i.e., patients who died in the first 24 h) to address survival
bias such that a patient who died early had less opportunity
to develop an infection.
A sensitivity analysis was performed, dividing our infec-
tion patients into 2 groups: infection within 48 h and
infection after 48 h of hospital admission. This analysis was
done to assess eventual differences in clinical outcomes
between early infection and nosocomial infection (or
hospital-acquired infection), defined as any infection that
occurred 48 h after hospital admission.
All analyses were conducted with SAS (version 9.2, SAS
Institute, Cary, North Carolina). The significance level was set
at 0.05. No adjustments were made for multiple comparisons.
Results
Baseline characteristics. Of 5,745 patients enrolled in the
PEX-AMI trial, 138 (2.4%) developed at least 1 serious
nfection. The median (25th, 75th percentile) time until
iagnosis of infection was 3 (1, 6) days, and 80% of the
nfections had already occurred by day 8 after hospital
dmission (Fig. 1). Most patients (n  96, 69.6%) devel-
ped a serious infection 48 h after hospital admission, and
nly 30.4% (n  42) developed infection before 48 h. The
ates of serious infections were similar between patients
reated with pexelizumab (2.3%) and placebo (2.5%).
Baseline characteristics of patients with and without
nfections are shown in Table 1. Patients with serious
nfections were older; more often had a history of a chronic
nflammatory condition, chronic obstructive pulmonary dis-
ase, and diabetes; and more often had anterior MI, Killip
lass III or IV, higher heart rate, higher creatinine value,
igher levels of peak creatine kinase, and creatine kinase
yocardial band levels with greater ST-segment deviation
han patients without infections. In addition, they had lower
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Figure 1. Rates of Serious Infection by Days in the Hospital
Infections were recorded to the day. Infections from randomization tos
day 1 (exclusive) were considered as occurring at day 0.uccess rates than those patients who did not develop serious
nfections (post-intervention Thrombolysis In Myocardial In-
arction [TIMI] flow grade 3, 75.4% vs. 90.3%, respectively).
In-hospital medications. In-hospital medications are listed
n Table 2. Patients with serious infection had numerically
ess use of statins, angiotensin-converting enzyme inhibi-
ors, beta-blockers, aspirin, and abciximab than patients
ithout serious infection.
In-hospital procedures. In-hospital procedures are described
n Table 3. In general, patients with serious infections had
umerically more in-hospital procedures than patients with-
ut serious infections, including repeat diagnostic catheter-
zation, additional PCI, cardiac surgery (coronary artery
ypass grafting), automatic implantable cardiac defibrillator
lacement, use of mechanical support (intra-aortic balloon
ump or left ventricular assist device), permanent pace-
aker placement, mechanical ventilation, echocardiogra-
hy, red blood cell transfusion, and dialysis. Similar results
ere observed when only serious infections that occurred
fter the procedures were analyzed (data not shown).
In-hospital complications. In-hospital complications are
hown in Table 4. Patients with serious infections had
umerically more in-hospital complications than patients
ithout serious infections, including recurrent ischemia,
trial fibrillation, ventricular tachycardia, ventricular fibril-
ation, cardiac arrest, deep venous thrombosis, renal failure,
nd bleeding. Similar results were seen when only compli-
ations that occurred after a serious infection were consid-
red (data not shown). Patients with versus without serious
nfection had longer length of hospital stay (12 vs. 5 days)
nd longer length of intensive care unit stay (7 vs. 2 days).
Serious infection features. Table 5 contains data about the
location of infections, number of infections per patient, and
organisms associated with infections. Most patients had
only 1 type of infection, the most common location being
the bloodstream, and the most common organism being
Staphylococcus aureus.
Clinical outcomes. Clinical outcomes are described in Table 6.
Rates of death, congestive heart failure, shock, MI, and
stroke were higher among patients with serious infection
compared with those without serious infection. Similar
results were observed when only clinical outcomes that
occurred after a serious infection were analyzed. Among
patients with serious infections, there was no difference in
clinical outcomes between patients treated with placebo or
pexelizumab.
After multivariable adjustment, serious infection was
significantly associated with 90-day death (adjusted HR:
5.3; 95% CI: 3.5 to 7.8, p  0.001) and death or MI
(adjusted HR: 4.6; 95% CI: 3.2 to 6.6, p 0.001). After the
exclusion of deaths that occurred in the first 24 h after acute
MI presentation (n  0 in the infection group and n  60
n the no infection group), serious infection remained
ignificantly associated with 90-day death (adjusted HR:
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772Table 1. Baseline Demographic Data and Other Characteristics
Serious Infection
(n  138)
No Serious Infection
(n  5,606)* p Value
Age, yrs 65 (57, 75) 61 (52, 71) 0.001
Female, % 26.1 23.0 0.394
Enrolled in the U.S. (yes), % 32.6 30.4 0.583
Transfer patient (yes), % 37.0 36.1 0.841
Anterior MI, % 70.3 58.9 0.007
Time from symptoms to hospital admission, h 2.3 (1.3, 3.8) 2.2 (1.3, 3.3) 0.581
Time from symptoms to randomization, h 3.1 (2.1, 4.2) 2.8 (2.0, 3.9) 0.116
Time from hospital admission to randomization, h 0.6 (0.3, 0.9) 0.5 (0.2, 0.9) 0.197
Systolic BP, mm Hg 129 (110, 148) 133 (117, 150) 0.017
Heart rate, beats/min 80 (65, 96) 75 (65, 86) 0.004
Diastolic BP, mm Hg 74.5 (65, 90) 80 (70, 90) 0.016
Height, cm 173 (165, 178) 172.7 (166, 178) 0.776
Weight, kg 80 (68, 90) 80 (70, 91) 0.436
Body mass index 26.7 (24.5, 29.6) 27.1 (24.5, 30.1) 0.683
CK value 140 (87, 361.2) 143.7 (90, 277) 0.794
Peak CK value 3,463 (1,525.8, 5,850) 1,771.1 (843, 3,261.5) 0.001
Creatinine value 97.2 (79.6, 114.9) 88.4 (79.6, 106.1) 0.001
CK-MB value 6.8 (3.3, 84) 4.6 (2.2, 14.8) 0.016
Peak CK-MB value 268.9 (147.3, 430) 157.8 (68, 292.1) 0.001
ST deviation, mm 15.5 (10, 21.3) 13 (9, 18.5) 0.004
Race, %
White vs. non-White 92.8 94.4 0.416
Smoking status, % 0.407
Never 37.0 33.2
Current 37.7 43.4
Past 25.4 23.4
Killip class, %
Class III or IV vs. I or II 10.1 1.6 0.001
Medical history, %
Atrial ﬁbrillation 6.5 4.1 0.156
Angina 26.1 24.0 0.568
CABG 2.2 2.2 1.000
CAD 21.7 16.3 0.087
CHF 9.4 3.5 0.001
Chronic inﬂammatory condition 6.5 1.7 0.001
Chronic liver disease 1.4 0.7 0.259
COPD 11.6 4.7 0.001
Current renal dialysis 0.7 0.3 0.323
Diabetes 22.5 15.7 0.033
Family history of CAD 16.2 19.0 0.411
ICH stroke 0.0 0.3 1.000
Hyperlipidemia 48.6 49.7 0.820
Hypertension 57.2 49.3 0.063
Post-intervention TIMI grade, % 0.001
Grade 0 4.8 2.5
Grade 1 3.2 0.9
Grade 2 16.7 6.4
Grade 3 75.4 90.3
Values are median (25th, 75th percentile) or %. *One patient developed an infection before the randomization and thus is excluded from the
denominator.
BP blood pressure; CABG coronary artery bypass grafting; CAD coronary artery disease; CHF congestive heart failure; CK creatine
kinase; CK-MB creatine kinase myocardial band; COPD chronic obstructive pulmonary disease; ECG electrocardiograph; ICH intracerebralhemorrhage; TIMI Thrombolysis In Myocardial Infarction.
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7735.6; 95% CI: 3.8 to 8.4, p  0.001) and death or MI
(adjusted HR: 4.9; 95% CI: 3.4 to 7.1, p  0.001). Similar
results were observed in patients who developed a serious
infection within 48 h of (n  42, 30.4%) and 48 h after
(n  96, 69.6%) hospital admission (data not shown).
Patients who presented in hospital with serious infection
were also more likely to be readmitted within 90 days for
another serious infection compared with patients who did
not develop a serious infection during index hospital stay for
acute MI (5.1% vs. 0.7%, respectively). Overall, when
compared with patients who did not have an infection,
those with any serious infection were also more likely to die
or be readmitted for any cause within 30 days (23.0% vs.
11.0%) and within 90 days (41.0% vs. 20.4%).
Table 2. In-Hospital Medications Used by Patients With and Without
Serious Infections
Medications Serious Infection No Serious Infection
Antibiotics 123/138 (89.1%) 662/5,606 (11.8%)
Aspirin 128/138 (92.8%) 5,444/5,601 (97.2%)
Thienopyridines 115/117 (98.3%) 5,206/5,249 (99.2%)
Abciximab 50/84 (59.5%) 2,527/3,903 (64.7%)
Eptiﬁbatide 25/84 (29.8%) 1,121/3,903 (28.7%)
Tiroﬁban 9/84 (10.7%) 255/3,903 (6.5%)
Statins 109/138 (79%) 5,118/5,602 (91.4%)
ACE inhibitors 98/138 (71%) 4,459/5,600 (79.6%)
Beta-blockers 97/138 (70.3%) 4,770/5,600 (85.2%)
Values are n/N (%).
ACE angiotensin-converting enzyme.
Table 3. In-Hospital Procedures in Patients With and Without
Serious Infections
Procedures Serious Infection No Serious Infection
Repeat diagnostic catheterization 18/138 (13.0%) 319/5,598 (5.7%)
Additional PCI (does not include
primary PCI for the qualifying MI)
12/138 (8.7%) 383/5,598 (6.8%)
Cardiac surgery (CABG) 23/138 (16.7%) 181/5,599 (3.2%)
Automatic implantable cardioverter-
deﬁbrillator
1/138 (0.7%) 28/5,599 (0.5%)
Intra-aortic balloon pump 55/138 (39.9%) 389/5,599 (7.0%)
Left ventricular assist device 3/138 (2.2%) 22/5,599 (0.4%)
Dialysis 6/138 (4.4%) 21/5,598 (0.4%)
Multi-uptake gated acquisition 0/138 (0%) 51/5,598 (0.9%)
Stress test 5/138 (3.6%) 191/5,598 (3.4%)
Cardiac MRI 2/138 (1.5%) 103/5,598 (1.8%)
Permanent pacemaker 2/138 (1.5%) 47/5,599 (0.8%)
Mechanical ventilation 52/138 (37.7%) 169/5,599 (3.0%)
Echocardiography 115/138 (83.3%) 3,866/5,594 (69.1%)
Red blood cell transfusion 48/138 (34.8%) 295/5,606 (5.3%)
Values are n/N (%).
CABG coronary artery bypass grafting; MRImagnetic resonance imaging; PCI percuta-aneous coronary intervention.Discussion
We demonstrated that, in a contemporary cohort of
STEMI patients who underwent primary PCI, serious
infection was rare, occurred at a median of 3 days after
presentation, and was more frequent among sicker patients
with a history of inflammatory disease, chronic obstructive
pulmonary disease, and diabetes and among those with
worse prognostic markers, such as higher creatinine level at
baseline, more advanced Killip class, higher heart rate, and
larger infarcts. These patients also had worse angiographic
results at the index PCI. Patients who underwent proce-
dures (e.g., coronary artery bypass grafting, intra-aortic
balloon pumping, dialysis) after the index PCI also more
frequently developed serious infections. Patients with infec-
tion also had more in-hospital complications other than
infection and had longer intensive care unit and hospital stays.
The most common site of infection was the bloodstream, and
the most commonly identified organism was Staphylococcus
aureus. Finally, serious infection was associated with 5-fold
higher rates of 90-day death and death or MI.
Fever and systemic inﬂammation in conjunction with MI. Pa-
ients with MI, particularly large MIs, can manifest fever at
resentation or during their hospital course, but it is
articularly common in the first 24 h after presentation and
oes not necessarily mean that an infection is present
18–21). However, it can often be a clinical challenge to
etermine whether the fever is due to the MI, to a
omplicating infection, or to other causes of systemic
nflammation. Regardless of the etiology, because fever has
Table 4. In-Hospital Complications in Patients With and Without
Serious Infections
Events
Serious Infection
(n  138)
No Serious Infection
(n  5,606)
Recurrent ischemia 9.4% 4.2%
Atrial ﬁbrillation 26.8% 6.4%
Ventricular tachycardia 12.3% 2.3%
Ventricular ﬁbrillation 12.3% 3.7%
Complete atrioventricular block 3.6% 1.6%
Electrical mechanical dissociation 1.4% 1.0%
Asystole 7.2% 2.1%
Cardiac arrest 10.1% 2.2%
Pericarditis 2.9% 1.2%
Cardiac tamponade 0.7% 0.3%
Acute mitral regurgitation 1.4% 0.2%
Acute ventricular septal defect 2.9% 0.1%
Ventricular rupture 2.2% 0.3%
Symptomatic hypotension 36.2% 8.8%
Pulmonary embolism 2.2% 0.0%
Deep venous thrombosis 0.7% 0.1%
Renal failure 20.3% 1.3%
Bleeding 44.9% 15.4%strong influence on oxygen consumption, it is important to
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774recognize preventable or treatable underlying causes of fever
that might predispose a patient to infarct extension and
greater infarct size (19,20).
The SHOCK (Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock) trial investi-
gators explored the systemic inflammatory state in patients
with cardiogenic shock complicating STEMI (22,23). They
concluded that inappropriate vasodilation in patients with
systemic inflammatory response syndrome might play an
important role in the pathogenesis and persistence of shock,
with or without infection (22). Although Ben-Dor et al.
(19) found that fever was frequent after reperfusion, they
concluded that it was due to infarct size and not to a
nonspecific systemic inflammatory response. In their study,
fever was correlated with high-sensitivity C-reactive protein
but not with fibrinogen levels or white blood cell count.
Subsequently, Naito et al. (20) found that fever after acute
MI was associated with worse clinical outcome and with
infarction expansion, suggesting a relationship between
systemic inflammatory response and left ventricular remod-
eling in the post-infarction period. Furthermore, the rates of
Table 5. Number of Infections, Location, Main Organisms, and
Distribution of Randomized Treatment for Infected Patients
Number of infections
1 107 (77.5)
2 25 (18.1)
3 5 (3.6)
5 1 (0.7)
Location of infection
Pleural effusion 1 (0.7)
Sputum 35 (25.4)
Tissue 1 (0.7)
Unlisted* 28 (20.3)
Urine 20 (14.5)
Blood 56 (40.6)
Wound 6 (4.3)
Organisms of infection
Culture contaminants 2 (1.4)
E. coli 10 (7.2)
Other 50 (36.2)
P. aeruginosa 7 (5.1)
Staph aureus 13 (9.4)
Staph. epidermis 5 (3.6)
Staph. species 8 (5.8)
Strep pneumonia 3 (2.2)
Strep. species 8 (5.8)
Unlisted† 28 (20.3)
Distribution of treatment for infected patients
Placebo 72 (52.2)
Pexelizumab 66 (47.8)
Values are n (%). *”Unlisted” is for patients who were infected but with no culture data.
†”Unlisted” is for patients who were infected but with no organism data.death due to pump failure, malignant arrhythmias, andcardiac failure increased significantly with increasing quar-
tile of body temperature (20).
Clinical infection after MI. Although fever tends to occur
ost commonly in the first 24 h after MI and might be
elated to infarct size, serious infection as a complication of
I seems to occur later in the hospital course. Although
revious literature is scarce with regard to primary PCI-
reated acute MI patients, in a cooperative study involving
ver 12,000 cardiac catheterizations, only 0.10% of patients
ad serious infection complications documented (9). One
ase-control study in stable patients who underwent elective
CI found that, similar to our results, infection after PCI
as most prevalent on day 3 after presentation and that
taphylococcus aureus was the most common organism (24).
nother study in elective PCI found that Staphylococcus epidermidis
as the most frequently identified organism associated with
ost-PCI infection. Together, these studies suggest that
nfection might be most related to instrumentation (25). As
ith our study, previous studies have suggested that con-
estive heart failure, multiple punctures in the same site,
ifficult vascular access, duration of sheath placement lasting
ore than 1 day, and longer duration of procedures are
mportant risk factors for bacteremia associated with cardiac
atheterization or PCI (10,24).
In a retrospective case-control study of 1,227 acute MI
atients admitted during the previous 47 months, 5% had
nfectious complications (26). In findings similar to ours,
atients with infections were older (67.5 vs. 62.6 years), had
onger length of hospital stay (26.7 vs. 12 days), and had
igher mortality (45% vs. 12%) compared with patients
ithout infections. The most common site of infection was
he lungs (63%), followed by the urinary tract (37%). Heart
nfections, such as purulent pericarditis and myocardial
bscess, after acute MI have been reported but are very
nfrequent (2,27–34).
Association of infection with clinical outcomes and length of
stay. Mortality associated with the presence of infection in
atients undergoing elective PCI with drug-eluting stents
as been estimated at 1% (35). However, mortality has
eached over 40% in some studies of infection after MI
24,26). In 1 prior study, the most common causes of death
Table 6. Clinical Outcomes in Patients With and Without Serious
Infections
Endpoints Serious Infection No Serious Infection
Death 40/138 (29.0%) 278/5,604 (5.0%)
CHF 32/138 (23.2%) 245/5,606 (4.4%)
Shock 28/138 (20.3%) 168/5,606 (3.0%)
MI 16/138 (11.6%) 174/5,601 (3.1%)
Stroke 9/138 (6.5%) 68/5,601 (1.2%)
Values are n/N (%).CHF congestive heart failure; MImyocardial infarction.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 7 , 2 0 1 2 Truffa et al.
J U L Y 2 0 1 2 : 7 6 9 – 7 6 Infection After Acute Myocardial Infarction
775in acute MI patients with infections were cardiogenic shock
(41%) and septic shock (30%) (26).
In our study of patients with STEMI treated with
primary PCI in the contemporary era, we demonstrated that
serious clinical infection was independently associated with
5-fold worse clinical outcomes, including mortality and
death or MI at 90 days. Importantly, these STEMI patients
with serious infection during the index hospital stay were
more likely to be readmitted to the hospital with another
serious infection within 90 days from discharge compared
with those patients who never developed an infection. Our
findings illustrate the importance of serious infection as a
marker of worse subsequent clinical outcomes in patients
with STEMI treated with primary PCI.
In addition to increased mortality and morbidity associ-
ated with serious infection in acute MI patients, serious
infections also seem to be associated with measures of
resource use. Whereas the length of stay after uncompli-
cated STEMI in the United States is approximately 4 to 5
days, length of stay in complicated STEMI has been shown
to average 11 days (36,37). In our study, we demonstrated
that patients with clinically diagnosed serious infections had
longer length of stay than patients without infections,
mirroring previous data on uncomplicated and complicated
MIs. Patients with serious infections also had lower rates of
post-intervention TIMI grade 3 flow compared with pa-
tients without infection. It is possible that longer procedure
times, more bleeding, and vascular access complications in
these patients could have contributed to a longer length of
stay. Conversely, these complications or low TIMI flow
grade itself might have resulted in the use of invasive
support devices like intra-aortic balloon pumps and other
in-dwelling lines or catheters that might have not only
increased the likelihood of developing a serious infection
during the course of hospital stay but also resulted in longer
hospital stay.
Another important related issue is the underlying defini-
tion of hospital infection. In general, a new infection
occurring in a patient during hospital stay at least 48 h after
admission is suspected to be nosocomial or hospital-
acquired. The rate of nosocomial infection has been pro-
posed as a measure of quality in patient care (38,39). In our
study, 96 (69.6%) patients who presented with a serious
infection did so 48 h after hospital admission. Interestingly,
in our overall cohort of patients who developed serious
infection, there were no differences in 90-day clinical
outcomes between those patients who developed a serious
infection within 48 h and those who did so after this time
window. These results highlight the importance of identi-
fying patients who are at risk for infection after PCI for
STEMI as well as seeking effective strategies for prevention,
both to improve clinical outcomes and to reduce resource
use. In addition, vigilance for early diagnosis and treatment
of those who develop infection is essential to minimizeserious complications. In particular, if a patient develops a
fever more than 24 h after presentation, this fever might not
be due to infarct size or systemic inflammatory response to
the infarction but rather might be an early sign of a serious
infection that could lead to worse clinical outcomes and
greater resource use.
Study limitations. First, this was an observational study;
therefore, a causal relationship between serious infection
and clinical outcomes cannot be established. In addition, it
is likely that in our study most serious infections were
hospital-acquired and related to instrumentation. Despite
our efforts and extensive statistical adjustments for impor-
tant confounders, we cannot fully tease out the influence of
pre-existing conditions predisposing a patient to infection
or of the infection itself that led to worse clinical outcomes.
Second, our population with infection was small, although
the larger APEX-AMI population with STEMI from which
they were drawn allowed us to define the contemporary
incidence of infection. Third, serious infection was determined
by the investigator and was not centrally adjudicated. However,
all in-hospital data from the case report forms were source
data-verified. In addition, discrepant data with regard to
infection were reconciled, and extensive data queries were
performed to verify the accuracy of the data. Finally, we did not
collect information on the specific treatments that were used
for serious infection in our patient population.
Conclusions
In the contemporary era, serious infections complicating the
course of patients with STEMI treated with primary PCI
were uncommon (2.4%) but were associated with worse
90-day clinical outcomes and longer hospital stays. The
most commonly identified organism was Staphylococcus au-
reus, and the main location was the bloodstream. Most
patients developed a serious infection 48 h after hospital
admission, and patients who developed any infection were
more likely to be re-admitted with another serious infection
within 90 days of hospital discharge. Further studies to
identify these high-risk patients as well as to design strate-
gies to reduce their risk of infection are warranted.
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